Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study

Background Selinexor, a first-in-class, oral selective inhibitor of nuclear export (SINE) compound inhibits Exportin-1(XPO1), had demonstrated synergistic activity with many chemotherapies and conferred in vivo antitumor efficacy in hematologic as well as solid tumors. Methods This open-label, singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Thein, Kyaw Zin, Piha-Paul, Sarina A., Tsimberidou, Apostolia, Karp, Daniel D., Janku, Filip, Zarifa, Abdulrazzak, Shah, Jatin, Milton, Denái R., Bean, Stacie, McQuinn, Lacey, Gong, Jing, Colen, Rivka, Carter, Brett W., Subbiah, Vivek, Ogbonna, Deby C., Pant, Shubham, Meric-Bernstam, Funda, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542012/
https://www.ncbi.nlm.nih.gov/pubmed/33909232
http://dx.doi.org/10.1007/s10637-021-01119-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542012/
https://www.ncbi.nlm.nih.gov/pubmed/33909232
http://dx.doi.org/10.1007/s10637-021-01119-0

Ejemplares similares